Greek Compassionate Use Program (CUP) of Polatuzumab-Vedotin in relapsed or refractory aggressive B-cell non-Hodgkin Lymphoma(B-NHL) patients
Latest Information Update: 01 Sep 2021
At a glance
- Drugs Bendamustine (Primary) ; Polatuzumab vedotin (Primary) ; Rituximab (Primary)
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Expanded access; Therapeutic Use
- 01 Aug 2021 Results published in the Hematological Oncology
- 22 Jul 2020 New trial record
- 21 Jun 2020 Results (n=46) presented at the 25th Congress of the European Haematology Association